Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities

Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs, non-specifically activating T cells, also leads to immune-mediated damage of tissue or immune-related adverse events (IRAE). IRAEs with rheumatic ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappelli, Laura C, Shah, Ami A, Bingham, Clifton O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Autoimmunity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051426/
https://www.ncbi.nlm.nih.gov/pubmed/27752360
http://dx.doi.org/10.1136/rmdopen-2016-000321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051426/
https://www.ncbi.nlm.nih.gov/pubmed/27752360
http://dx.doi.org/10.1136/rmdopen-2016-000321

Ejemplares similares